These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8852331)

  • 1. Protein kinase inhibitors--potential chemotherapeutic agents.
    Shugar D
    Acta Biochim Pol; 1995; 42(4):405-18. PubMed ID: 8852331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of inhibitors of protein kinases CKI and CKII and some related aspects, including donor and acceptor specificities and viral protein kinases.
    Shugar D
    Cell Mol Biol Res; 1994; 40(5-6):411-9. PubMed ID: 7735315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NTP phosphate donor in kinase reactions: is ATP a monopolist?
    Shugar D
    Acta Biochim Pol; 1996; 43(1):9-23. PubMed ID: 8790708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets.
    Legraverend M; Grierson DS
    Bioorg Med Chem; 2006 Jun; 14(12):3987-4006. PubMed ID: 16503144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
    Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO; McInnes C
    Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-nucleoside inhibitors of herpesviruses.
    Wathen MW
    Rev Med Virol; 2002; 12(3):167-78. PubMed ID: 11987142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of polymerase inhibitors as antiviral drugs.
    Oberg B
    Antiviral Res; 2006 Sep; 71(2-3):90-5. PubMed ID: 16820225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Src tyrosine kinase substrate binding site inhibitors.
    Ye G; Tiwari R; Parang K
    Curr Opin Investig Drugs; 2008 Jun; 9(6):605-13. PubMed ID: 18516760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are MAP kinases drug targets? Yes, but difficult ones.
    Margutti S; Laufer SA
    ChemMedChem; 2007 Aug; 2(8):1116-40. PubMed ID: 17541990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting protein kinases in cancer therapy.
    Fabbro D; García-Echeverría C
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):701-12. PubMed ID: 12630290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
    J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. dUTP pyrophosphatase as a potential target for chemotherapeutic drug development.
    McIntosh EM; Haynes RH
    Acta Biochim Pol; 1997; 44(2):159-71. PubMed ID: 9360704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
    Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.